Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propiomazine is a phenothiazine derivative classified as an antihistamine and sedative. It is primarily used to treat insomnia and to provide sedation or relieve anxiety before or during surgery and other procedures. Propiomazine may also be used in combination with analgesics during labor. While structurally related to antipsychotics like clozapine and sometimes described as an atypical antipsychotic agent, it is not therapeutically used as a neuroleptic because it does not block dopamine receptors strongly enough for that purpose. Its main pharmacological action is antagonism of histamine H1 receptor (antihistaminic effect), which accounts for its sedative properties. Additionally, propiomazine acts as an antagonist at dopamine (D1, D2, D4), serotonin (5-HT2A and 5-HT2C), muscarinic acetylcholine (M1–M5), and alpha-1 adrenergic receptors[2][3][6][8]. The drug has oral bioavailability of about 33%, high protein binding (~81%), and an elimination half-life of approximately 9 hours[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propiomazine.